ABSTRACT
Gastroesophageal reflux disease (GERD) is a common condition worldwide. Despite numerous studies on GERD, the causal relationships between blood/urine metabolites and GERD remain unclear. This study aims to explore the causal relationships between GERD and 35 blood/urine metabolites. In this study, we conducted Mendelian randomization (MR) analyses for 35 blood/urine metabolites with GERD phenotypes from the FinnGen R10 and UKB databases separately. We then performed a meta-analysis of the inverse variance weighted results from the 2 MR analyses and applied multiple corrections to the significant P values from the meta-analysis. Finally, we conducted reverse causality validation for the corrected positive blood/urine metabolite phenotypes with GERD. After conducting MR analysis combined with meta-analysis and performing multiple corrections, we found significant positive causal associations between only 3 blood/urine metabolites and GERD, with no significant reverse associations. Among them, 2 are risk factors for the occurrence of GERD: alanine aminotransferase levels (odds ratio (OR)â =â 1.120, 95% confidence interval (CI)â =â 1.064-1.180, Pâ =â .0005) and urate levels (ORâ =â 1.095, 95% CIâ =â 1.044-1.147, Pâ =â .005). Additionally, sex hormone-binding globulin levels are protective against GERD (ORâ =â 0.928, 95% CIâ =â 0.896-0.961, Pâ =â .0009). Elevated levels of the metabolites alanine aminotransferase and urate are associated with an increased risk of GERD, identifying them as risk factors for the condition. In contrast, higher levels of SHBG are linked to a decreased risk of GERD, indicating that SHBG is a protective factor against the disease.
Subject(s)
Gastroesophageal Reflux , Mendelian Randomization Analysis , Uric Acid , Humans , Gastroesophageal Reflux/blood , Uric Acid/blood , Sex Hormone-Binding Globulin/analysis , Sex Hormone-Binding Globulin/metabolism , Risk Factors , Alanine Transaminase/blood , Biomarkers/blood , PhenotypeABSTRACT
BACKGROUND: Laparoscopic sleeve gastrectomy combined with fundoplication (LSGFD) can significantly control body weight and achieve effective anti-reflux effects. The aim of this study is to investigate the correlation between the alteration in Ghrelin levels and weight loss following SGFD, and to compare Ghrelin levels, weight loss and metabolic improvements between SG and SGFD, with the objective of contributing to the existing body of knowledge on SGFD technique in the management of patients with obesity and gastroesophageal reflux disease (GERD). METHODS: A retrospective analysis was conducted on the clinical data of 115 obese patients who underwent bariatric surgery between March 2023 and June 2023 at the Department of Minimally Invasivew Surgery, Hernia and Abdominal Wall Surgery, People's Hospital of Xinjiang Uygur Autonomous Region. The subjects were divided into two groups based on surgical methods: sleeve gastrectomy group (SG group, 93 cases) and sleeve gastrectomy combined with fundoplication group (SGFD group, 22 cases). Clinical data, such as ghrelin levels before and after the operation, were compared between the two groups, and the correlation between changes in ghrelin levels and weight loss effectiveness after the operation was analyzed. RESULTS: Three months after the operation, there was no significant difference in body mass, BMI, EWL%, fasting blood glucose, triglyceride, cholesterol, and uric acid levels between the SG and SGFD groups (P > 0.05). However, the SGFD group exhibited a significant decrease in body weight, BMI, and uric acid levels compared to preoperative levels (P < 0.05), while the decrease in ghrelin levels was not statistically significant (P > 0.05). Logistic regression analysis indicated that ghrelin levels three months after the operation were influential in postoperative weight loss. CONCLUSION: The reduction of plasma Ghrelin level in patients after SGFD is not as obvious as that in patients after SG, but it can make obese patients get the same good weight loss and metabolic improvement as patients after SG. Ghrelin level at the third month after operation is the influencing factor of postoperative weight loss.
Subject(s)
Fundoplication , Gastrectomy , Gastroesophageal Reflux , Ghrelin , Weight Loss , Humans , Ghrelin/blood , Weight Loss/physiology , Male , Female , Gastrectomy/methods , Retrospective Studies , Adult , Fundoplication/methods , Gastroesophageal Reflux/surgery , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/etiology , Middle Aged , Obesity, Morbid/surgery , Obesity, Morbid/blood , Laparoscopy/methods , Bariatric Surgery/methods , Treatment OutcomeABSTRACT
OBJECTIVE: To observe the effect of acupuncture on gastroesophageal reflux disease (GERD) based on the "heart-stomach connection" theory, and to explore its possible mechanisms. METHODS: Seventy patients with GERD were randomly divided into an acupuncture group (35 cases, 2 cases dropped out) and a medication group (35 cases, 1 case dropped out). The patients in the acupuncture group received acupuncture at bilateral Shenmen (HT 7), Neiguan (PC 6), Burong (ST 19), Tianshu (ST 25), Zusanli (ST 36), Gongsun (SP 4), and Zhongwan (CV 12), with needles retained for 30 min, every other day, three times a week. The patients in the medication group were treated with oral omeprazole capsules, once daily, 20 mg each time. Both groups were treated for 8 weeks. Before and after treatment, the GERD questionnaire (GERDQ), GERD-quality of life scale (GERD-QOL), Hamilton depression scale-24 (HAMD-24), Zung self-rating depression scale (SDS), and Zung self-rating anxiety scale (SAS) scores were observed. Serum levels of gastrointestinal hormones (gastrin [GAS], motilin [MTL], and vasoactive intestinal peptide [VIP]) were measured, and the clinical efficacy of both groups was evaluated. Correlation between pre-treatment GERDQ score and GERD-QOL score, HAMD-24 score, SDS score, and SAS score was analyzed. RESULTS: After treatment, the scores of GERDQ, HAMD-24, SDS, and SAS were decreased (P<0.001) and the scores of GERD-QOL were increased (P<0.001), serum levels of GAS and MTL were increased (P<0.001) in both groups, while the serum level of VIP in the acupuncture group was decreased (P<0.001) compared with those before treatment. The acupuncture group had higher GERD-QOL score and lower SAS score than the medication group (P<0.05), with lower serum VIP level (P<0.05). The total effective rate was 75.8% (25/33) in the acupuncture group, and 76.5% (26/34) in the medication group, with no significant difference between the two groups (P>0.05). GERDQ score was negatively correlated with GERD-QOL scores (r =-0.762, P<0.01) and positively correlated with HAMD-24 score, SDS score, and SAS score (r =0.709, 0.649, 0.689, P<0.01) before treatment. CONCLUSION: Based on the "heart-stomach connection" theory, acupuncture could effectively improve clinical symptoms, quality of life, and negative emotions in patients with GERD. Its mechanism may be related to the regulation of gastrointestinal hormone levels, thereby promoting the contraction of the lower esophageal sphincter.
Subject(s)
Acupuncture Therapy , Gastroesophageal Reflux , Humans , Gastroesophageal Reflux/therapy , Gastroesophageal Reflux/blood , Male , Female , Middle Aged , Adult , Aged , Gastrointestinal Hormones/blood , Acupuncture Points , Young Adult , Stomach/physiopathology , Heart/physiopathology , Motilin/bloodABSTRACT
Eosinophilic esophagitis (EoE) is often misdiagnosed as GERD; therefore, the goal of the current study is to establish a non-invasive diagnostic and monitoring biomarker that differentiated GERD from EoE. Reports indicates that IL-15 responsive iNKT cells and tissue specific IgE have a critical in EoE pathogenesis, not in GERD. Therefore, we tested the hypothesis that the panel of IL-15-responsive T cell and IgE receptors may be novel non-invasive biomarkers for EoE. Accordingly, the receptors of IL-15 responsive T cells (Vα24, Jα18, γδT, αßT) and IgE (FcεRI & FcεRII) were examined. The data indicates that blood mRNA levels of Vα24, Jα18, γδ T, αß T and FcεRI are significantly reduced in EoE compared to the GERD patients and normal individuals. The ROC curve analysis indicated FcεRII, Jα18 and δ TCR are the positive predictors that discriminate EoE from GERD. Thus, these molecules will be a novel non-invasive diagnostic biomarker for EoE.
Subject(s)
Eosinophilic Esophagitis/blood , Gastroesophageal Reflux/blood , RNA, Messenger/blood , Receptors, Antigen, T-Cell/genetics , Receptors, IgE/genetics , Receptors, Interleukin-15/genetics , Adolescent , Child , Child, Preschool , Diagnosis, Differential , Eosinophilic Esophagitis/diagnosis , Eosinophilic Esophagitis/pathology , Female , Gastroesophageal Reflux/diagnosis , Humans , Male , Natural Killer T-Cells/metabolism , ROC Curve , Receptors, Antigen, T-Cell, alpha-beta/genetics , Receptors, Antigen, T-Cell, gamma-delta/genetics , Young AdultABSTRACT
BACKGROUND AND AIMS: In clinical practice, most patients with symptoms suggestive of gastroesophageal reflux disease (GERD) undergo esophago-gastro-duodenoscopy (EGD), despite its low sensitivity in detecting reflux stigmata. Gastrin 17 (G-17) has been proposed to be related with GERD, due to the negative feedback between acid secretion and this hormone. We assessed the clinical usefulness of fasting G-17 serum determination for a non-invasive diagnosis of GERD in patients with typical symptoms. METHODS: We consecutively enrolled patients complaining of typical GERD symptoms in two different settings: a single referral center and a primary care setting. Control groups consisted of dyspeptic patients. All subjects underwent assessment of serum levels of G-17 and EGD. RESULTS: At the academic hospital, 100 GERD patients (n=89 with erosive esophagitis and 11 with Barrett's esophagus) had statistically significant low levels of G-17 as compared with 184 dyspeptic patients (1.7±1.2 pg/L vs 8.9±5.7 pg/L p<0.0001). Similarly, in the primary care setting, 163 GERD patients had statistically significant low levels of G-17 as compared with 132 dyspeptic patients (0.5±0.2 pg/L vs. 4.0±2.6 pg/L, p<0.0001). Moreover, in the primary care setting, no statistically significant differences were found for G-17 levels between patients with erosive and non-erosive reflux pattern (0.4±0.2 vs 0.7±0.3; p=0.08). In primary care, the accuracy of G-17 less than 1 pg/L to diagnose non-invasively GERD was 94.3%. CONCLUSIONS: Low levels of G-17 were detected in patients with erosive esophagitis and Barrett's esophagus in a referral center and in patients with typical GERD symptoms in a sample of patients from a primary care setting.
Subject(s)
Esophagitis, Peptic/blood , Esophagitis, Peptic/pathology , Esophagoscopy , Gastrins/blood , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/pathology , Adult , Aged , Esophagitis, Peptic/complications , Female , Gastroesophageal Reflux/complications , Humans , Male , Middle AgedABSTRACT
Eosinophilic esophagitis (EoE) is an allergic inflammatory disease of the esophagus that occurs in both children and adults. Previous studies of affected tissue from pediatric cohorts have identified prominent signatures of eosinophilia and type 2 inflammation. However, the details of the immune response in adults with EoE are still being elucidated. To determine whether EoE in adults shares inflammatory profiles with those observed in children, we performed RNA sequencing of paired human esophageal biopsies and blood samples from adults with EoE or gastroesophageal reflux disease. Unbiased analysis of differentially expressed genes in tissue revealed a strong IFN signature that was significantly enriched in EoE patients as compared with patients with gastroesophageal reflux disease. Both type I and type II IFN-responsive genes were upregulated in adult biopsies, but not in blood. A similar increase in expression of IFN gene sets was observed in pediatric EoE biopsies as compared with non-EoE samples, and in public pediatric and adult RNA-sequencing data. Finally, we found that human peripheral CD4+ T cells from children with EoE produce IFN-γ upon activation with EoE-causal allergens. Together, this work identifies a conserved IFN signature in pediatric and adult EoE, highlighting a role for non-type 2 inflammatory networks in the disease process in humans.
Subject(s)
Eosinophilic Esophagitis/immunology , Esophagus/pathology , Gastroesophageal Reflux/immunology , Interferon Type I/metabolism , Interferon-gamma/metabolism , Adolescent , Adult , Age Factors , Aged , Biopsy , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Case-Control Studies , Child , Child, Preschool , Eosinophilic Esophagitis/blood , Eosinophilic Esophagitis/pathology , Esophagus/immunology , Female , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/pathology , Gene Expression Profiling , Humans , Male , Middle Aged , Sequence Analysis, RNA , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Transcriptome/immunology , Up-Regulation/immunology , Young AdultABSTRACT
Metoclopramide is commonly used for gastroesophageal reflux. The aims of the present study were to develop a pediatric population pharmacokinetic (PopPK) model, which was applied to simulate the metoclopramide exposure following dosing used in clinical practice. Opportunistic pharmacokinetic data were collected from pediatric patients receiving enteral or parenteral metoclopramide per standard of care and these data were simultaneously fitted using NONMEM. Allometric scaling with body weight was included a priori in the model. Using the final model, the steady-state maximum concentrations (Css,max ) and the area under the metoclopramide plasma concentration-time curve at steady state from 0 to 6 hours (AUCss,0-6h ) were simulated following 0.1 or 0.15 mg/kg orally every 6 hours in virtual patients, and compared with previously reported ranges associated with toxicity or the efficacy for gastroesophageal reflux in infants. A two-compartment model with first-order absorption best characterized 87 concentration measurements from 50 patients (median [range] postnatal age of 8.89 years [0.01-19.13]). There were 20 infants (≤ 2 years), 9 children (2 years to age ≤ 12 years), and 21 adolescents (> 12 years). Body weight was the only covariate included in the final model. For > 75% of virtual patients, simulated Css,max and AUCss,0-6h estimates were within the range associated with efficacy for gastroesophageal reflux in infants; however, slightly lower exposures were predicted in virtual patients < 2 years. Our study suggests that a metoclopramide enteral dose of 0.1 mg/kg every 6 hours, which was previously recommended for pediatric patients, results in simulated exposure generally within suggested ranges for the treatment of gastroesophageal reflux.
Subject(s)
Gastroesophageal Reflux/drug therapy , Metoclopramide/pharmacokinetics , Models, Biological , Adolescent , Area Under Curve , Body Weight , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Gastroesophageal Reflux/blood , Humans , Infant , Infant, Newborn , Male , Metoclopramide/administration & dosage , Metoclopramide/adverse effects , Treatment Outcome , Young AdultABSTRACT
Objective: Gastroesophageal reflux disease (GERD) is an important cause of chronic cough. Substance P (SP) has been implicated in the pathophysiology of cough. Proton pump inhibitors (PPIs) and prokinetic agents are the current treatment for GER-associated cough. The aim was to evaluate the effects of anti-reflux treatment and its associations with cellular and neurogenic inflammation.Methods: Thirty-seven patients with GER-associated cough suspected based on characteristic symptoms such as heartburn and worsening of cough by phonation and rising were recruited. A PPI, rabeprazole 20 mg daily, and a prokinetic agent, itopride 50 mg t.i.d., were administered for 4 weeks in a prospective, observational manner. Before and after treatment, subjective cough measures [visual analog scale (VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ)], the modified frequency scale for the symptoms of GERD [FSSG, consisting of 2 domains: acid-reflux (AR) and functional dyspepsia symptoms], sputum and plasma SP levels, and sputum cell differentials were examined. Patients with good response to treatment [Δ (decrease of) VAS >15 mm; n = 21) were compared with poor responders (ΔVAS ≤15 mm).Results: Anti-reflux treatment significantly improved the cough VAS, J-LCQ, and AR symptoms, and ΔVAS and ΔAR were significantly correlated. Decreases of plasma and sputum SP levels and sputum neutrophil counts were significantly greater in responders than in poor responders. Both baseline values and post-treatment changes of plasma SP and sputum neutrophils were significantly correlated for all patients.Conclusions: Successful treatment of GER-associated cough may be associated with the attenuation of neurogenic and neutrophilic inflammation.
Subject(s)
Cough/immunology , Gastroesophageal Reflux/drug therapy , Neutrophils/immunology , Proton Pump Inhibitors/therapeutic use , Substance P/metabolism , Adult , Aged , Chronic Disease , Cough/blood , Cough/diagnosis , Female , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/immunology , Humans , Inflammation/blood , Inflammation/immunology , Leukocyte Count , Male , Middle Aged , Prospective Studies , Rabeprazole/therapeutic use , Severity of Illness Index , Sputum/chemistry , Sputum/cytology , Substance P/analysis , Treatment Outcome , Visual Analog ScaleABSTRACT
BACKGROUND: For eosinophilic esophagitis (EoE) recently an association with immunoglobulin (Ig)G4 rather than IgE has been reported. Gastroesophageal reflux disease (GERD) is the most important differential diagnosis of EoE. We compared esophageal IgG4 plasma cell infiltration and serum IgG4 levels of EoE patients (before and after budesonide therapy) with GERD patients. METHODS: Prospectively collected serum samples of 17 EoE patients before and after 8 weeks of therapy with budesonide (1 mg BID) were analyzed for total and antigen-specific IgG4 and IgE levels. Also, immunohistochemical analysis of total and IgG4-positive plasma cells was performed on esophageal biopsies of these patients. In total, 14 GERD patients without histologic proof of eosinophilic infiltration were taken as a control group. RESULTS: Total IgG4 serum levels in EoE patients were significantly higher than in GERD patients (121.0 vs. 71.2 mg/dL; P=0.038) and decreased under budesonide therapy (121.0 vs. 104.2 mg/dL; P=0.019). IgE levels did not differ significantly between all groups. In EoE patients also a high number of esophageal IgG4-positive plasma cells was detected and significantly reduced under therapy (29.1 vs. 0.1 IgG4-positive cells; P<0.001). In GERD patients no relevant esophageal plasma cell infiltration could be seen. CONCLUSIONS: In EoE patients elevated systemic IgG4 serum levels compared with GERD patients can be seen and decrease under topical steroid therapy. Also, local IgG4 plasma cells expression is high in EoE, but not in GERD patients and normalize under therapy. These findings are further proof for a possible association of EoE with IgG4.
Subject(s)
Eosinophilic Esophagitis/blood , Eosinophilic Esophagitis/diagnosis , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/diagnosis , Immunoglobulin G/blood , Adult , Aged , Biopsy , Budesonide/therapeutic use , Clinical Trials as Topic , Diagnosis, Differential , Eosinophilic Esophagitis/drug therapy , Esophagus/pathology , Female , Humans , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
BACKGROUND: Acid exposure time (AET) prolongation plays an important role in the pathogenesis of gastroesophageal reflux disease (GERD). Gastric inhibitory polypeptide (GIP) and pancreatic polypeptide (PP) participate in the regulation of gastric acid secretion, blood glucose and lipid levels, and food intake. In this study, we evaluated the serum GIP and PP levels in refractory GERD patients and analyzed their metabolic and motility characteristics. METHODS: Seventy-three refractory GERD patients were enrolled in this study from September 2015 to September 2017. We investigated the clinical characteristics, severity, and duration of GERD symptoms. High-resolution manometry and 24 hours impedance-pH monitoring were performed to assess esophageal motility and reflux parameters. The patients were divided into the AET- group (AET <4.2%) and AET+ group (AET >4.2%). GIP and PP levels were determined in all subjects and their associations with other parameters evaluated. RESULTS: Age and GERDQ score were significantly higher (Pâ<â.05) and acid reflux and heartburn more frequent in the AET+ group than in the AET- group. The contraction front velocity was increased in the AET- group, while there was no significant difference in the distal contraction integral, peristalsis interruption, distal latency, or resting pressures of the lower and upper esophageal sphincters between the 2 groups (Pâ>â.05). The serum levels of GIP (Pâ=â.003) and PP (Pâ=â.012) were significantly increased in the AET+ group. Increased GIP and PP levels were associated with abnormal upright AET (correlation coefficients 0.307 and 0.233, Pâ=â.008 and Pâ=â.047). There was a positive correlation between GIP and triglyceride levels (correlation coefficient 0.279, Pâ=â.017). CONCLUSION: The serum levels of GIP and PP in refractory GERD patients with prolongation of AET are significantly elevated, mainly in the upright position.
Subject(s)
Gastric Acid/metabolism , Gastric Inhibitory Polypeptide/blood , Gastroesophageal Reflux/blood , Pancreatic Polypeptide/blood , Time Factors , Aged , Electric Impedance , Esophageal pH Monitoring , Esophagus/physiopathology , Female , Gastroesophageal Reflux/physiopathology , Humans , Male , Manometry , Middle AgedABSTRACT
The effects of comorbidities on systemic inflammation markers in stable asthmatics and the consequences of such effects have not been well evaluated. We aimed to evaluate the effect of comorbidities on clinical manifestations and systemic inflammation in asthmatic patients under control. The study group consisted of asthmatic patients who applied to our pulmonology outpatient clinic and volunteered to participate. 120 clinically stable asthma patients (71 females and 49 males) and 35 healthy controls (19 females and 16 males) with similar age, gender, and body mass index distributions were admitted to the study. The levels of osteopontin, interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 13 (IL-13), eosinophilic cationic protein, adiponectin, and high-sensitivity C-reactive protein of the individuals were evaluated using commercial ELISA kits by taking venous blood samples. Of 120 asthmatic subjects, 47 (39, 2%) had comorbidities and allergic rhinitis (15%) coexisted most frequently. Other comorbidities associated with asthma were gastroesophageal reflux, sinusitis, hypertension, diabetes, gastritis, and peptic ulcus respectively. There was no physician-diagnosed comorbidity in the control group. The levels of IL-6 and IL-8 were found higher in asthma group with comorbidities when compared to those with no comorbidities (p were 0.032 and 0.046, respectively). Comorbidities interfere with the diagnosis and treatment of asthma, besides affecting the disease control. Our findings suggest the possibility of the impact of comorbidities on systemic inflammation markers, especially IL-6 and IL-8. To evaluate the impact of comorbidities on asthma control and systemic markers, further studies are needed.
Subject(s)
Asthma/blood , Asthma/epidemiology , Intercellular Signaling Peptides and Proteins/blood , Adolescent , Adult , Biomarkers/blood , C-Reactive Protein/analysis , Comorbidity , Diabetes Mellitus/blood , Diabetes Mellitus/epidemiology , Female , Gastritis/blood , Gastritis/epidemiology , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/epidemiology , Humans , Hypertension/blood , Hypertension/epidemiology , Male , Middle Aged , Rhinitis/blood , Rhinitis/epidemiology , Sinusitis/blood , Sinusitis/epidemiology , Young AdultSubject(s)
Anemia/etiology , Esophageal Mucosa/pathology , Esophageal Neoplasms/diagnosis , Gastroesophageal Reflux/etiology , Lymphoma, B-Cell, Marginal Zone/diagnosis , Aged , Anemia/blood , Biopsy , Endoscopy, Digestive System , Endosonography , Esophageal Mucosa/diagnostic imaging , Esophageal Neoplasms/blood , Esophageal Neoplasms/complications , Esophageal Neoplasms/drug therapy , Female , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/diagnostic imaging , Humans , Infusions, Intravenous , Lymphoma, B-Cell, Marginal Zone/blood , Lymphoma, B-Cell, Marginal Zone/complications , Lymphoma, B-Cell, Marginal Zone/drug therapy , Positron Emission Tomography Computed Tomography , Rituximab/administration & dosage , Treatment OutcomeABSTRACT
PURPOSE: The vitamin D receptor (VDR) endocrine system has emerged as an endogenous pleiotropic biological cell regulator with anti-neoplastic effects on breast, colorectal, and prostatic adenocarcinomas. We studied the association of gene expression, polymorphisms of VDR, CYP27B1, and CYP24A1 genes and serum vitamin D levels as surrogate markers of disease progression in patients with acid reflux, Barrett's esophagus (BE), or esophageal adenocarcinoma (EAC). METHODS: We analyzed blood and tissue samples from patients with biopsy-confirmed BE or EAC for vitamin D levels, gene expressions, and polymorphisms in VDR (FokI [F/f], BsmI [B/b], ApaI [A/a], and TaqI [T/t]), CYP27B1 (HinfI [H/h]), and CYP24A1 (Hpy1881 [Y/y]). Percentages of homozygous dominant/recessive or heterozygous traits were assessed for each polymorphism in all patient subgroups. RESULTS: Genomic Bb and FF polymorphisms were highly prevalent in EAC patients, whereas BE patients had a high prevalence of wild-type Hpy1881 (YY polymorphism). Some polymorphisms (Yy for CYP24A1, bb for VDR) were noted only in EAC patients. Yy and bb forms were both uniquely present in some EAC patients without associated Barrett's lesions, but not in patients with concomitant BE. AA and bb polymorphisms were associated with decreased response to neoadjuvant therapy. A high level of VDR and CYP24A1 mRNA expression was observed in EAC tissue of non-responders. Serum vitamin D deficiency was common in EAC patients. CONCLUSIONS: Specific polymorphisms in vitamin D metabolism-related genes are associated with the likelihood of reflux-BE-EAC progression. Identifying such polymorphisms may aid in development of better surveillance and diagnostic and therapeutic protocols.
Subject(s)
Adenocarcinoma/genetics , Barrett Esophagus/genetics , Biomarkers, Tumor/genetics , Esophageal Neoplasms/genetics , Gastroesophageal Reflux/genetics , Vitamin D/analogs & derivatives , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/blood , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Adenocarcinoma/blood , Adenocarcinoma/metabolism , Adenocarcinoma/therapy , Adult , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Barrett Esophagus/blood , Barrett Esophagus/metabolism , Barrett Esophagus/pathology , Biomarkers, Tumor/blood , Biomarkers, Tumor/metabolism , Biopsy , Case-Control Studies , Disease Progression , Drug Resistance, Neoplasm/genetics , Esophageal Mucosa/pathology , Esophageal Neoplasms/blood , Esophageal Neoplasms/metabolism , Esophageal Neoplasms/therapy , Esophagectomy , Female , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/metabolism , Gastroesophageal Reflux/pathology , Genetic Predisposition to Disease , Healthy Volunteers , Humans , Male , Middle Aged , Neoadjuvant Therapy/methods , Polymorphism, Single Nucleotide , Receptors, Calcitriol/blood , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Treatment Outcome , Vitamin D/blood , Vitamin D/metabolism , Vitamin D3 24-Hydroxylase/blood , Vitamin D3 24-Hydroxylase/genetics , Vitamin D3 24-Hydroxylase/metabolismABSTRACT
BACKGROUND: One-quarter of systemic symptoms associated with chronic spontaneous urticaria (CSU) are related to gastrointestinal complaints (GICs). OBJECTIVES: To investigate the prevalence and features of urticaria-overlapping GICs. METHODS: In this retrospective cross-sectional survey, 1426 consecutive outpatients were observed at our University Department. Only patients suffering from urticaria or GICs with a complete diagnostic work-up including serum total IgE level (Tot-IgE), differential blood count and urticaria activity score (UAS), were evaluated. RESULTS: Among different GICs, gastroesophageal reflux disease (GERD) was the most frequent syndrome observed (15.4%; 95%CI: 13.6-17.3). The prevalence of overlap syndrome for urticaria and GERD was 5.9% (95%CI: 4.7-7.2). In urticaria-patients, the prevalence of GERD was four-fold higher than in patients without hives (44% vs. 11%, p<0.001). UAS was significantly higher in urticaria and GERD overlap syndromes vs. isolated urticarias. In patients with GERD or acute/chronic urticaria or overlap syndrome, Tot-IgE and eosinophil blood count (EBC) differed significantly, with a stepwise increase in their values; from the subgroup of patients with GERD only, to that with overlap of CSU to GERD. Prevalence values for urticaria overlapping with GERD were three- and two-fold higher in CSU and in long-duration GERD cases respectively compared to acute urticaria or short-duration GERD cases. Similar to Th2 pathology models, CSU and GERD overlap syndrome was significantly and independently associated with Total-IgE ≥100IU/ml or EBC ≥250/mmc compared to CSU or GERD. Endoscopic/bioptic findings of non-erosive reflux disease (NERD) or Barrett's esophagus (BE) were more frequent in chronic overlap syndrome than in GERD-patients. CONCLUSIONS: GERD was the most frequent GIC in patients with urticaria. Overlap syndrome was more frequent among patients with CSU, where this syndrome was associated with higher values of UAS, Tot-IgE, EBC and frequencies of NERD and BE. These results suggest that overlap syndrome is frequently a chronic syndrome with a Th2-like profile.
Subject(s)
Eosinophils/cytology , Gastroesophageal Reflux/epidemiology , Immunoglobulin E/blood , Urticaria/epidemiology , Adult , Comorbidity , Cross-Sectional Studies , Female , Gastroesophageal Reflux/blood , Humans , Leukocyte Count , Male , Middle Aged , Prevalence , Retrospective Studies , Severity of Illness Index , Urticaria/blood , Young AdultABSTRACT
The association between gastroesophageal reflux disease (GERD) prevalence and its risk factors in an area with low Helicobacter pylori prevalence is important to clarify. We analyzed the prevalence of GERD and risk factors in an area of Indonesia with low prevalence of H. pylori infection. We recruited 104 dyspeptic patients who underwent endoscopy in Surabaya. Patients were diagnosed with GERD based on the Los Angeles classification. We evaluated gastric biopsy specimens and measured serum pepsinogen levels. Interleukin polymorphisms were evaluated by polymerase chain reaction-restriction fragment length polymorphism. Of 104 patients, 56 (53.8%) were endoscopically found to have GERD, with most categorized as grade A; 48 (46.2%) were classified as non-GERD. Higher economic status, smoking, and a history of proton-pump inhibitor use significantly increased the risk of GERD. GERD Questionnaire scores showed a positive correlation with GERD (P < 0.001). An association was found between antral atrophic gastritis and GERD (P = 0.030), and patients with GERD more frequently had severe antral atrophy than nonerosive reflux disease (P = 0.018). We found an association between pepsinogen I/II levels and GERD (P = 0.047), but with low accuracy. IL-1ß -511 TT and CT were predominant among the IL-1ß -511 genotypes, and IL-8-251 AT and TT were predominant among the IL-8-251 genotypes. In conclusion, we found a high prevalence of GERD in an area with low prevalence of H. pylori infection, which could be associated with acid reflux. Smoking, history of proton-pump inhibitor use, and higher economic group significantly increased the risk of GERD.
Subject(s)
Gastritis/genetics , Gastroesophageal Reflux/genetics , Helicobacter Infections/genetics , Helicobacter pylori/pathogenicity , Adolescent , Adult , Aged , Biopsy , Endoscopy , Female , Gastritis/blood , Gastritis/microbiology , Gastritis/pathology , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/microbiology , Gastroesophageal Reflux/pathology , Genotype , Helicobacter Infections/blood , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/genetics , Humans , Interleukin-1beta/genetics , Interleukin-8/genetics , Male , Middle Aged , Pepsinogen A/blood , Polymorphism, Single Nucleotide , Risk Factors , Smoking/genetics , Young AdultABSTRACT
The aim of this study was to determine the relationships between free testosterone (FT) level and parameters including laboratory data and data from questionnaires and to determine symptoms leading to the detection of late onset hypogonadism (LOH). We retrospectively reviewed medical records of patients in whom serum FT was measured in our hospital. Aging Male Symptoms (AMS) score, self-rating depression scale (SDS) and frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) score were used for questionnaires. A total of 205 patients were included in the analysis (55.2 ± 15.6 years of age, mean ± SD). Among them, 119 patients (58.0%) had an FT level of less than 8.5 pg/mL, which fulfills the diagnostic criterion of LOH syndrome according to the clinical practice manual for LOH in Japan. It was revealed that FSSG score was inversely correlated to serum FT levels (r = -0.3395, p < 0.001), although SDS and AMS scales did not show significant correlations to FT levels. Our study revealed a high prevalence of LOH syndrome among patients in whom the majority complained of general symptoms. Although GERD symptoms are generally not considered to be typical symptoms of LOH, our study indicates that those symptoms might be clues for the detection of LOH.
Subject(s)
Gastroesophageal Reflux/blood , Testosterone/blood , Adult , Aged , Aged, 80 and over , Female , Gastroesophageal Reflux/diagnosis , Humans , Male , Middle Aged , Retrospective Studies , Surveys and Questionnaires , Symptom Assessment , Young AdultABSTRACT
OBJECTIVE: Introduction: The question of the combination and combined influence of the gastroesophageal reflux disease (GERD) and many other chronic diseases of internal medicine, including diabetes, have not been studied enough. The aim: To investigate the changes in cholecystokinin (CCK) levels in blood serum of patients with GERD on the background of type II diabetes. PATIENTS AND METHODS: Materials and methods: On the basis of the propaedeutics of internal diseases department of the medical faculty of the SHEI "UzhNU" during the period of 2016 - 2017, 48 patients were examined for type II diabetes with GERD (main group: group I). The comparison group comprised 18 patients with GERD (group II). All of the patients had their blood serum cholecystokinin levels examined with the help of enzyme-linked immunosorbent assay (ELISA) using the test system of the "Peninsula Laboratories" (USA) company. RESULTS: Results: The gathered data points to an increase of the CCK levels in blood serum in patients with GERD, as compared to the indices of the control group. This being said, we can highlight that in patients with the background of combined pathology, type II diabetes and GERD in particular, the level of CCK exceeds the average by 6 times, whereas in patients with GERD (comparison group) it exceeds only by 2.4 times. Further analysis of the gathered results points out an interesting pattern in the changes of blood serum CCK levels in patients with GERD on the background of type II diabetes depending on the BMI, in particular - the maximal indices were observed in patients with excess body weight. CONCLUSION: Conclusions: In patients with GERD an increase of CCK level is observed, as compared to the indices of healthy individuals. The combination of GERD and type II diabetes is accompanied by a more prominent increase of CCK in blood serum, with a correlation between the disorder of the nutritional status and the CCK level had been established, namely - its maximal indices in patients with excess body weight.
Subject(s)
Cholecystokinin/blood , Diabetes Mellitus, Type 2/blood , Gastroesophageal Reflux/blood , Diabetes Mellitus, Type 2/complications , Gastroesophageal Reflux/complications , HumansABSTRACT
Gastroesophageal reflux disease (GERD), a clinical condition characterized by reflux of gastroduodenal contents in the oesophagus, has proved to demonstrate a strong link between oxidative stress and the development of GERD. Proton pump inhibitors (PPIs) have been universally accepted as first-line therapy for management of GERD. The potential benefits of electrolysed reduced water (ERW), rich in molecular hydrogen, in improving symptoms and systemic oxidative stress associated with GERD was assessed. The study was performed on 84 GERD patients undergoing control treatment (PPI + tap water) or experimental treatment (PPI + ERW) for 3 months. These patients were subjected to the GERD-Health Related Quality of Life Questionnaire as well as derivatives reactive oxigen metabolites (d-ROMs) test, biological antioxidant potential (BAP) test, superoxide anion, nitric oxide and malondialdehyde assays, which were all performed as a proxy for the oxidative/nitrosative stress and the antioxidant potential status. Spearman's correlation coefficient was used to evaluate the correlation between scores and laboratory parameters. Overall results demonstrated that an optimal oxidative balance can be restored and GERD symptoms can be reduced rapidly via the integration of ERW in GERD patients. The relative variation of heartburn and regurgitation score was significantly correlated with laboratory parameters. Thus, in the selected patients, combination treatment with PPI and ERW improves the cellular redox state leading to the improvement of the quality of life as demonstrated by the correlation analysis between laboratory parameters and GERD symptoms.
Subject(s)
Gastroesophageal Reflux/blood , Gastroesophageal Reflux/therapy , Hydrogen/therapeutic use , Water/pharmacology , Adult , Aged , Antioxidants/metabolism , Humans , Middle Aged , Oxidation-Reduction , Oxidative Stress/drug effects , Proton Pump Inhibitors/therapeutic use , Quality of Life , Young AdultABSTRACT
This document serves as an update of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) 2009 clinical guidelines for the diagnosis and management of gastroesophageal reflux disease (GERD) in infants and children and is intended to be applied in daily practice and as a basis for clinical trials. Eight clinical questions addressing diagnostic, therapeutic and prognostic topics were formulated. A systematic literature search was performed from October 1, 2008 (if the question was addressed by 2009 guidelines) or from inception to June 1, 2015 using Embase, MEDLINE, the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Clinical Trials. The approach of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) was applied to define and prioritize outcomes. For therapeutic questions, the quality of evidence was also assessed using GRADE. Grading the quality of evidence for other questions was performed according to the Quality Assessment of Studies of Diagnostic Accuracy (QUADAS) and Quality in Prognostic Studies (QUIPS) tools. During a 3-day consensus meeting, all recommendations were discussed and finalized. In cases where no randomized controlled trials (RCT; therapeutic questions) or diagnostic accuracy studies were available to support the recommendations, expert opinion was used. The group members voted on each recommendation, using the nominal voting technique. With this approach, recommendations regarding evaluation and management of infants and children with GERD to standardize and improve quality of care were formulated. Additionally, 2 algorithms were developed, 1 for infants <12 months of age and the other for older infants and children.
Subject(s)
Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/therapy , Adolescent , Antacids/therapeutic use , Biomarkers/blood , Child , Child, Preschool , Combined Modality Therapy , Complementary Therapies , Diagnosis, Differential , Endoscopy, Gastrointestinal , Esophageal pH Monitoring , Fundoplication , Gastroesophageal Reflux/blood , Humans , Infant , Infant, Newborn , Manometry , Medical History Taking , Nutritional Support , Physical Examination , Prognosis , Proton Pump Inhibitors/therapeutic useABSTRACT
Magnesium deficiency can cause a variety of symptoms, including potentially life-threatening complications such as seizures, cardiac arrhythmias and secondary electrolyte disturbances. Hypomagnesemia can be a serious adverse effect to proton pump inhibitor (PPI) therapy, which is worrying due to the widespread use of PPIs. Current evidence suggest that the mechanism of PPI induced hypomagnesemia is impaired intestinal magnesium absorption. In this report, we present the case of a long-term PPI user with persistent hypomagnesemia with severe symptoms at presentation. He was unable to stop PPI treatment because of severe reflux symptoms, and was dependent on weekly intravenous magnesium infusions, until his magnesium levels finally normalized without the need for supplementation after a successful laparoscopic fundoplication.